Hematology/Oncology and Cell and Gene Therapy Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Multifactorial and Complex Phenotype Research Area, Bambino Gesù Children's Hospital-IRCCS, Rome, Italy.
J Exp Clin Cancer Res. 2024 Oct 9;43(1):282. doi: 10.1186/s13046-024-03197-3.
Rhabdomyosarcoma (RMS) is the most common pediatric soft tissue sarcoma, with embryonal (ERMS) and alveolar (ARMS) representing the two most common histological subtypes. ARMS shows poor prognosis, being often metastatic at diagnosis. Thus, the discovery of novel biomarkers predictive of tumor aggressiveness represents one of the most important challenges to overcome and may help the development of tailored therapies. In the last years, miRNAs carried in extracellular vesicles (EVs), small vesicles of endocytic origin, have emerged as ideal candidate biomarkers due to their stability in plasma and their tissue specificity.
EVs miRNAs were isolated from plasma of 21 patients affected by RMS and 13 healthy childrens (HC). We performed a miRNA profile using the Serum/Plasma Focus microRNA PCR panels (Qiagen), and RT-qPCR for validation analysis. Statistically significant (p < 0.05) miRNAs were obtained by ANOVA test.
We identified nine EVs miRNAs (miR-483-5p, miR-132-3p, miR-766-3p, miR-454-3p miR-197-3p, miR-335-3p, miR-17-5p, miR-486-5p and miR-484) highly upregulated in RMS patients compared to HCs. Interestingly, 4 miRNAs (miR-335-5p, miR-17-5p, miR-486-5p and miR-484) were significantly upregulated in ARMS samples compared to ERMS. In the validation analysis performed in a larger group of patients only three miRNAs (miR-483-5p, miR-335-5p and miR-484) were differentially significantly expressed in RMS patients compared to HC. Among these, mir-335-5p was significant also when compared ARMS to ERMS patients. MiR-335-5p was upregulated in RMS tumor tissues respect to normal tissues (p = 0.00202) and upregulated significantly between ARMS and ERMS (p = 0.04). Furthermore, the miRNA expression correlated with the Intergroup Rhabdomyosarcoma Study (IRS) grouping system, (p = 0.0234), and survival (OS, p = 0.044; PFS, p = 0.025). By performing in situ hybridization, we observed that miR-335-5p signal was exclusively in the cytoplasm of cancer cells.
We identified miR-335-5p as significantly upregulated in plasma derived EVs and tumor tissue of patients affected by ARMS. Its expression correlates to stage and survival in patients. Future studies are needed to validate miR-335-5p as prognostic biomarker and to deeply elucidate its biological role.
横纹肌肉瘤(RMS)是最常见的小儿软组织肉瘤,其中胚胎性(ERMS)和肺泡性(ARMS)是最常见的两种组织学亚型。ARMS 预后较差,通常在诊断时就已经转移。因此,发现新的能够预测肿瘤侵袭性的生物标志物是最重要的挑战之一,这可能有助于制定针对性的治疗方法。近年来,细胞外囊泡(EVs)中携带的 miRNA 作为理想的候选生物标志物脱颖而出,这些 miRNA 是小的内吞起源的囊泡,由于其在血浆中的稳定性和组织特异性而受到关注。
从 21 名 RMS 患者和 13 名健康儿童(HC)的血浆中分离 EVs miRNA。我们使用 Serum/Plasma Focus microRNA PCR 面板(Qiagen)进行 miRNA 谱分析,并进行 RT-qPCR 验证分析。通过方差分析(ANOVA)检验获得具有统计学意义(p < 0.05)的 miRNA。
我们鉴定了 9 种在 RMS 患者中高度上调的 EVs miRNA(miR-483-5p、miR-132-3p、miR-766-3p、miR-454-3p miR-197-3p、miR-335-3p、miR-17-5p、miR-486-5p 和 miR-484)。有趣的是,与 ERMS 相比,4 种 miRNA(miR-335-5p、miR-17-5p、miR-486-5p 和 miR-484)在 ARMS 样本中显著上调。在对更大患者群体进行的验证分析中,只有 3 种 miRNA(miR-483-5p、miR-335-5p 和 miR-484)在 RMS 患者与 HC 之间存在差异表达。其中,miR-335-5p 在 ARMS 与 RMS 患者之间也具有显著差异。miR-335-5p 在 RMS 肿瘤组织中相对于正常组织上调(p = 0.00202),并且在 ARMS 与 RMS 之间显著上调(p = 0.04)。此外,miRNA 表达与 Intergroup Rhabdomyosarcoma Study(IRS)分组系统相关(p = 0.0234),与生存(OS,p = 0.044;PFS,p = 0.025)相关。通过原位杂交,我们观察到 miR-335-5p 信号仅存在于癌细胞的细胞质中。
我们鉴定了 miR-335-5p 在 ARMS 患者的血浆衍生 EVs 和肿瘤组织中显著上调。其表达与患者的分期和生存相关。需要进一步的研究来验证 miR-335-5p 是否可作为预后生物标志物,并深入阐明其生物学作用。